The presence of sex differences in immunological functioning influences hidradenitis suppurativa (HS).
The female sex bias in hidradenitis suppurativa (HS) is probably multifaceted, with contributions from hormones, genetics, environmental influences, and the microbiome on changes in the immune system, according to a review in Frontiers in Immunology.
HS is a debilitating inflammatory disease that shows a strong female sex vias in multiple studies. It is characterized by immune dysregulation, including elevated levels of myeloid cells, T helper (Th) cells, and pro-inflammatory cytokines, especially those involved in Th1- and Th17-mediated immunity.
Despite this, former studies evaluating the immunological profiles of patients with HS have not noted stratified results between biologic females and males. Additionally, sex differences in the response to immunomodulatory HS biologics have not been extensively studied.
This review evaluated the role of intrinsic and extrinsic influences that add to immunological differences between the sexes and postulate their role in the female sex bias seen in HS. The researchers discuss the effects of hormones, X chromosome dosage, genetics, the microbiome, and smoking on sex-related differences in immunity to hypothesize possible immunological mechanisms in the pathophysiology of HS.
Of interest, the researchers noted that differences in sex-biased immune processes might explain some of the expanding literature supporting sex-biased comorbidities associated with HS. However, in some of the comorbidities, the sex difference was not significant, like psoriasis.
Further, although estrogens and androgens may have opposing roles in developmental processes, present data highlight their influence on the immune response is likely because of combined interactions and relative changes in concentrations leading to immune problems.
Growing numbers of studies involve a role for the microbiome in sex-biased immunity. Some studies have pinpointed sex-related alterations in the cutaneous microbiome, which may result from differences between the sexes in hormone metabolism, rates of perspiration, and skin pH. Additionally, differences in the immune system, like those previously described, might affect how females respond to changes in the microbiome.
Although antigen specificity has not been defined as a feature of HS, innate and humoral immune responses are obvious features of HS, and evidence of the effects of hormones, X-chromosome dosage, and sex-biased genes on immunological pathways emphasizes possible contributors to the female sex bias in HS. The clinical efficacy of cytokine blocking immunotherapy, like adalimumab, secukinumab, and brodalumab, supports a position for inflammatory cytokines as key disease mediators.
Hormonal fluctuations during puberty, the menstrual cycle, pregnancy, and menopause have been linked with the start of HS and/or HS flares in some patients, emphasizing that the effect of sex hormones on the cutaneous immune system may contribute to HS pathogenesis.
Multiple studies have also linked HS with acne, hirsutism, and polycystic ovarian syndrome, backing a role for androgens on disease. Additionally, recent case reports have explained new-onset and exacerbations of HS symptoms in gender dysphoric patients receiving supplemental testosterone therapy.
Of note, some patients report clinical improvement with anti-androgen therapy, but the specific roles of different hormones have not been well studied in HS pathophysiology. The researchers say that future studies elucidating the effects of sex hormones on inflammasome activation or immune cell function in patients with HS might support a mechanistic link for hormones in the mystery of HS pathophysiology.
More studies will assist in clarifying the molecular mechanisms of non-hormone and non-sex chromosome-related sex-biased gene expression.
Larger studies are needed to establish whether sex-related immunity linked with alterations in the gut microbiome might play a role in HS. Additionally, more studies are needed to explore the gut-skin axis and see if alterations in the gut microbiome may affect the cutaneous inflammation seen in HS.
The trend of male sex bias in HS was found from several studies in Asia, and probably represents a significant role of environmental influences on HS within the context of ancestry-specific genomic features. Smoking was described as one of the most substantiated environmental risk factors for HS.
In addition to the inflammation associated with smoking, chemicals like nicotine may disrupt skin metabolism, and future studies examining this might provide more context into how smoking might directly influence immune cells in patients with HS.
The researchers said that it will be vital to consider sex-based efficacy of immunomodulatory drugs in future trials in patients with HS considering the multiple potential sex-based immunological contribution to HS.
“A better understanding of sex-specific effects may also help reframe and improve management of HS in a more effective and equitable manner,” concluded the researchers.
Reference
Young KZ, Dimitrion P, Zhou L, Adrianto I, Mi QS. Sex-biased immunological processes drive hidradenitis suppurativa. Front Immunol. Published online May 4, 2023. doi:10.3389/fimmu.2023.1167021
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More